Research progress of circulating tumor DNA detection in radiotherapy

doi:10.3760/cma.j.issn.1673-422X.2018.06.007

Abstract

Abstract: Circulating tumor DNA (ctDNA) refers to the DNA segment of the free tumor located in the peripheral circulation, which carries the biologic information derived from the tumor. In recent years, the innovation of the second generation sequencing technology has expanded the prospect of the clinical application of ctDNA analysis. Detection of ctDNA has made a great progress in the field of radiation therapy, especially in the aspect of evaluating the sensitivity of radiotherapy. ctDNA in peripheral blood is characterized by convenient extraction and high specificity. Detection of ctDNA is not only conducive to find minimal residual disease and metastasis, but also help clinicians better evaluate the curative effect and judge prognosis after radiotherapy, which will provide a new way of thinking for the diagnosis and treatment strategy of tumor.

Key words: Radiotherapy, Neoplasms, Biological markers, Prognosis, Circulating tumor DNA

Wang Tuo, Li Guixiang. Research progress of circulating tumor DNA detection in radiotherapy[J]. Journal of International Oncology, 2018, 45(6): 352-354.

References

［1］ Baumann M, Krause M, Overgaard J, et al. Radiation oncology in the era of precision medicine［J］. Nat Rev Cancer, 2016, 16(4): 234-249. DOI: 10.1038/nrc.2016.18. ［2］刘斌亮. 循环肿瘤DNA在乳腺癌内分泌治疗耐药中的应用［J］. 国际肿瘤学杂志, 2017, 44(10): 779-782. DOI: 10.3760/cma.j.issn.1673-422X.2017.10.014. ［3］ Yao W, Mei C, Nan X, et al. Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: a qualitative study［J］. Gene, 2016, 590(1): 142-148. DOI: 10.1016/j.gene.2016.06.033. ［4］ Ulrich BC, Paweletz CP. Cellfree DNA in oncology: gearing up for clinic［J］. Ann Lab Med, 2018, 38(1): 18. DOI: 10.3343/alm.2018.38.1.1. ［5］ Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early and latestage human malignancies［J］. Sci Transl Med, 2014, 6(224): 224ra24. DOI: 10.1126/ scitranslmed.3007094. ［6］ Zhao L, Fong AHW, Liu N, et al. Molecular subtyping of nasopharyngeal carcinoma (NPC) and a microRNAbased prognostic model for distant metastasis［J］. J Biomed Sci, 2018, 25(1): 16. DOI: 10.1186/s1292901804175. ［7］ Chen QY, Guo SY, Tang LQ, et al. Combination of tumor volume and EpsteinBarr virus DNA improved prognostic stratification of stage Ⅱ nasopharyngeal carcinoma in the IMRT era: a largescale cohort study［J］. Cancer Res Treat, 2017, In press. DOI: 10.4143/crt.2017.237. ［8］ Chen M, Yin L, Wu J, et al. Impact of plasma EpsteinBarr virusDNA and tumor volume on prognosis of locally advanced nasopharyngeal carcinoma［J］. Biomed Res Int, 2015, 2015: 617949. DOI: 10.1155/2015/ 617949. ［9］ Chen WH, Tang LQ, Guo SS, et al. Prognostic value of plasma EpsteinBarr virus DNA for local and regionally advanced nasopharyngeal carcinoma treated with cisplatinbased concurrent chemoradiotherapy in intensitymodulated radiotherapy era［J］. Medicine (Baltimore), 2016, 95(5): e2642. DOI: 10.1097/MD.0000000000002642. ［10］ Ben Lassoued A, Nivaggioni V, Gabert J. Minimal residual disease testing in hematologic malignancies and solid cancer［J］. Expert Rev Mol Diagn, 2014, 14(6): 699-712. DOI: 10.1586/14737159.2014.927311. ［11］ Ahn SM, Chan JY, Zhang Z, et al. Saliva and plasma quantitative polymerase chain reactionbased detection and surveillance of human papillomavirusrelated head and neck cancer［J］. JAMA Otolaryngol Head Neck Surg, 2014, 140(9): 846-854. DOI: 10.1001/jamaoto.2014.1338. ［12］ Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage［J］. Nat Med, 2014, 20(5): 548-554. DOI: 10.1038/nm.3519. ［13］ Chaudhuri AA, Binkley MS, Osmundson EC, et al. Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA［J］. Semin Radiat Oncol, 2015, 25(4): 305-312. DOI: 10.1016/j.semradonc.2015.05.001. ［14］ Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer［J］. N Engl J Med, 2013, 368(13): 1199-1209. DOI: 10.1056/ NEJMoa1213261. ［15］ Bidard FC, Madic J, Mariani P, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma［J］. Int J Cancer, 2014, 134(5): 1207-1213. DOI: 10.1002/ijc.28436. ［16］ Dahlstrom KR, Li G, Hussey CS, et al. Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer［J］. Cancer, 2015, 121(19): 34553464. DOI: 10.1002/cncr.29538. ［17］ JamalHanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of nonsmallcell lung cancer［J］. N Engl J Med, 2017, 376(22): 2109-2121. DOI: 10.1056/ NEJMoa1616288. ［18］ Jeong Y, Hoang NT, Lovejoy A, et al. Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance［J］. Cancer Discov, 2017, 7(1): 86-101. DOI: 10.1158/ 2159-8290.CD160127. ［19］ Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts earlystage lung cancer evolution［J］. Nature, 2017, 545(7655): 446-451. DOI: 10.1038/nature22364.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[6]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[7]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[8]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[9]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[10]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[11]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[12]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[13]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[14]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[15]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.